Gliocure is a specialized pharmaceutical company in the field of neuro-oncology, dedicated to providing hope to patients suffering from glial diseases, particularly those with brain tumors. Since late 2016, Gliocure has established the necessary operational capabilities and expertise in translational research and pharmaceutical sciences to identify, select, and develop new molecules of interest in neuro-oncology, leading up to the authorization of initial clinical trials. One of their key developments is GC01, a best-in-class anti-tumor and neuro-protective peptide, backed by over 10 years of academic research, for which Gliocure holds exclusive worldwide rights.

Currently in the late non-regulatory preclinical development stage, GC01 targets the treatment of glioblastoma (GBM), the most common and aggressive brain tumor. Gliocure also offers comprehensive research solutions to transform molecules of interest in neuro-oncology into potential drug candidates. Find out more about Gliocure's portfolio, products, and developments on their website